Video Series

Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront combination therapy over sequential treatment in mantle cell lymphoma.

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with operational efficiency and cost savings serving as added benefits rather than decision drivers.

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T feasibility, expansion, and durability compared with later-line treatment.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement for patients with Alzheimer disease.

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer disease agitation therapies.

Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is essential for managing a chronic condition like follicular lymphoma.

Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.

Panelists discuss how balancing adverse-effect management with adherence optimization drives effective therapy transitions.

Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy.

Discussion of patient selection criteria, logistical challenges, toxicity management, and when to favor each immunotherapy approach.

Examination of how combination therapy and next-generation immunotherapies are poised to redefine RRMM treatment over the next 5 years.

Experts discuss the unmet needs in desmoid tumor management, emphasizing personalized treatment, quality of life, and the importance of specialized care.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.

Experts discuss the challenges of diagnosing rare diseases and the potential role of AI in improving patient management and treatment outcomes.

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted education to ensure earlier therapy and better patient outcomes.

Explore the integration of Desmoid Tumor Working Group recommendations with NCCN guidelines and the importance of shared decision-making in patient care.

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating comprehensive, multidisciplinary supportive care including pulmonary rehabilitation and comorbidity management.

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct strengths and limitations. IV administration offers established dosing precision, flexibility for complex regimens, and familiarity across oncology practices, but it is often associated with longer chair time, higher staffing demands, and increased use of infusion resources. In contrast, SC injections provide a more streamlined approach, with shorter administration times and reduced need for infusion infrastructure. Emerging evidence suggests that SC formulations can meaningfully decrease health care utilization, improve clinic efficiency, and enhance patient convenience without compromising clinical outcomes. For patients, SC delivery may translate into less time in the clinic and a more favorable treatment experience, while practices may benefit from improved throughput and optimized resource allocation. Together, these considerations highlight the growing value of SC formulations in evolving oncology care models.

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, and long-term safety data to reduce costly treatment-resistant depression.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.